ACADIA PHARMACEUTICALS INC
ACAD · Healthcare · $4.4B mkt cap · FY2025 filings · Shallow moat ·
Doesn't clear the bar
The four filters
Median gross margin 94.4% over 10y, very stable.
Median ROIC -47.5%, above the 9% hurdle in 20% of years.
Net cash position — no leverage risk.
Owner earnings trend unclear, share count growing (dilution).
Margin of safety
- Owner earnings (normalized)
- —
- Est. intrinsic value / share
- —
- Recent price
- $25.60
- Discount to value
- No price data
Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
18 years of fundamentals
The business, in plain English
ACADIA PHARMACEUTICALS INC booked $1.1B of revenue in FY2025 in the Healthcare sector and kept 91.7% of it as gross profit — a high-margin business by that measure. After every other cost, 36.5% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $6.4M (FY2009) to $1.1B (FY2025) — about 37.7% a year compounded over 16 years.
It earned 10.0% on invested capital in FY2025, with a median of −47.5% across 16 filed years. The Returns on Capital filter above scores it 7/100.
The balance sheet carried $32000 of total debt in FY2011. Balance-Sheet Safety scores it 100/100.
The share count rose 332.8% between FY2010 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 24/100.
Put together: Balance-Sheet Safety is the strongest of the four filters (100/100) and Returns on Capital the weakest (7/100), which is how ACAD lands at 56/100 — a Shallow moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in ACAD’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
None yet — ACAD has read Shallow moat for every logged capture since Jul 17, 2026.
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#91 of 440 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #89BVS BIOVENTUS INC.56.4 out of 100, Shallow moatShallow moat
- #90IMAX IMAX Corporation56.3 out of 100, Shallow moatShallow moat
- #92TDY TELEDYNE TECHNOLOGIES INC55.9 out of 100, Shallow moatShallow moat
- #93BRKR BRUKER CORPORATION55.9 out of 100, Shallow moatShallow moat
Compare ACAD with its nearest peers →All Healthcare companies on the Index →
Common questions about ACAD
- Does ACADIA PHARMACEUTICALS INC have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores ACADIA PHARMACEUTICALS INC (ACAD) 56.2 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 98, returns on capital 7, balance-sheet safety 100, capital discipline 24.
- How has ACAD's Moat Score changed over time?
- The record logs 3 readings since Jul 17, 2026; the latest reads 56.2 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.